RELEASE: CRT 2023 selects the Syntach cardiac assistance system for the Best Innovation Contest

(Information sent by the signatory company).

RELEASE: CRT 2023 selects the Syntach cardiac assistance system for the Best Innovation Contest

(Information sent by the signatory company)

LUND, Sweden, Feb. 22, 2023 /PRNewswire/ -- Syntach AB ("Syntach") is pleased to announce that the company's Syntach (Syntach CS) cardiac assist system has been selected for an oral presentation in the Competition to Best Innovation to be held at the 2023 CRT Annual Meeting at the Omni Shoreham Hotel in Washington, DC, February 25-28, 2023. Syntach's technology is also in the running for the 2023 CRT Best Innovation Award. The announcement The winner's award will be made at the FDA Town Hall Luncheon on Tuesday, February 28, 2023.

Cardiovascular Research Technologies (CRT) is a leading educational forum on new cardiovascular technologies and procedures for physicians and healthcare professionals. CRT provides an exemplary training forum for interventional cardiologists, general cardiologists, cardiothoracic and vascular surgeons, catheterization laboratory managers, nurses and technologists, scientists, and all others interested in cardiovascular medicine. To join the interventional and endovascular specialists at CRT 2023, email

More than 64 million people suffer from heart failure, one of the most frequent causes of death worldwide. The Syntach Heart Assist System is a novel device and treatment method designed to enhance natural motion designed to restore the heart's natural pump by acting on the motion of the mitral valve plane during the cardiac cycle, making each heartbeat be more effective. This technology does not require open-heart surgery and is powered by an implanted battery, avoiding a conduction line through the skin and many of the negative side effects associated with available assistive devices.

Monica Tocchi, MD, PhD, and CEO and Founder of Meditrial USA Inc (Meditrial), will present Syntach's innovative heart assist system in a talk titled "Fully Implantable, Minimally Invasive Heart Assist Technology to Restore Cardiac Function in Patients with heart failure" during the Innovations HUB:

Syntach and Meditrial have recently announced a partnership to support the development of clinical and regulatory strategies for Syntach's innovative minimally invasive heart support system.

"We are delighted to be working with Syntach on this innovative technology," said Monica Tocchi, MD, cardiologist and CEO of Meditrial. "Syntach CS is based on recent research and new insights into the importance of mitral valve plane displacement, which accounts for 60% of left ventricular stroke volume. Independent studies have shown the correlation of this factor in cardiac dysfunction with reduced of survival and major adverse cardiac events in patients with heart failure.Excellent preclinical results have been obtained in animal models of heart failure by restoring the natural motion of the mitral plane.Clinical trials are planned to demonstrate that this device has the potential to increase the cardiac functionality and improve clinical outcomes."

"We are pleased that Syntach CS is participating in this year's Best Innovation Contest," said Patrick NJ Schnegelsberg, CEO of Syntach. "CRT's annual meeting offers educational and training sessions focused on discussing new trial data, exploring evidence-based research, and presenting the most up-to-date techniques that can be directly applied to clinical and academic practices. This is the first This is the time that Syntach CS will be presented at a major conference, and I am grateful for the recognition of our innovative therapeutic approach to address a critical unmet need for heart failure patients."

Patrick NJ Schnegelsberg (CEO, Syntach) and Kristian Solem (VP Clinical & IP Affairs, Syntach) will be attending CRT2023 and you can contact them at Dr. Monica Tocchi will attend at

Syntach AB is headquartered in Lund, Sweden and develops innovative cardiac assist systems as well as mitral valve intervention systems in cooperation with several academic research centers. Syntach works with the Cardiac MR Group of the Department of Clinical Sciences and Clinical Physiology at Lund University. The academic team at Lund University has pioneered research into the functioning of the heart.

Logo -

View original content: